

1 **Expression changes in immune and epigenetic gene pathways associated with**
2 **nutritional metabolites in maternal blood from pregnancies resulting in autism and**
3 **atypical neurodevelopment**

4
5 Yihui Zhu^{1,2}, yhzhu@ucdavis.edu

6 Charles E. Mordaunt^{1,2}, cemordaunt@ucdavis.edu

7 Blythe P Durbin-Johnson³, bpdurbin@ucdavis.edu

8 Marie A Caudill⁴, mac379@cornell.edu

9 Olga V. Malysheva⁴, ovm4@cornell.edu

10 Joshua W. Miller⁵, jmiller@sebs.rutgers.edu

11 Ralph Green⁶, rgreen@ucdavis.edu

12 S. Jill James⁷, JamesJill@uams.edu

13 Stepan B. Melnyk⁷, Melnyksb@archildrens.org

14 M. Daniele Fallin⁸, dfallin@jhu.edu

15 Irva Hertz-Picciotto^{2,3}, iher@ucdavis.edu

16 Rebecca J. Schmidt^{2,3}, rjschmidt@ucdavis.edu

17 Janine M. LaSalle^{1,2*}, jmlasalle@ucdavis.edu

18 * Corresponding author

19 1. Department of Medical Microbiology and Immunology, Genome Center, and Perinatal

20 Origins of Disparities Center, University of California, Davis, CA, 95616, USA

21 2. MIND Institute, School of Medicine, University of California, Davis, CA, 95616, USA

22 3. Department of Public Health Sciences, University of California, Davis, CA, 95616, USA

23 4. Division of Nutritional Sciences, Cornell University, Ithaca, NY, 14850, USA

24 5. Department of Nutritional Sciences, Rutgers University, New Brunswick, NJ, 08854, USA

25 6. Department of Pathology and Laboratory Medicine, University of California Davis School
26 of Medicine, Sacramento, CA, 95817, USA

27 7. Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas
28 Children's Research Institute, 4301 W Markham St, Little Rock, AR,
29 72205, USA

30 8. Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins
31 University, Baltimore, Maryland, USA

32

33 **Abstract**

34 **Background:** The prenatal period is a critical window to study factors involved in the
35 development of autism spectrum disorder (ASD). Environmental factors, especially *in utero*
36 nutrition, can interact with genetic risk for ASD, but how specific prenatal nutrients in
37 mothers of children later diagnosed with ASD or non-typical development (Non-TD)
38 associate with gestational gene expression is poorly understood. Maternal blood collected
39 prospectively during pregnancy provides a new opportunity to gain insights into nutrition,
40 particularly one-carbon metabolites, on gene pathways and neurodevelopment.

41 **Methods:** Genome-wide transcriptomes were measured using microarrays in 300
42 maternal blood samples from all three trimesters in the Markers of Autism Risk in Babies -
43 Learning Early Signs (MARBLES) study. Sixteen different one-carbon metabolites, including
44 folic acid, betaine, 5'-methyltetrahydrofolate (5-MeTHF), and dimethylglycine (DMG) were
45 measured. Differential expression analysis and weighted gene correlation network analysis

46 (WGCNA) were used to compare gene expression between children later diagnosed as
47 typical development (TD), Non-TD and ASD, and to nutrient metabolites.

48 **Results:** Using differential gene expression analysis, six transcripts associated with four
49 genes (*TGR-AS1*, *SQSTM1*, *HLA-C* and *RFESD*) showed genome-wide significance (FDR $q <$
50 0.05) with child outcomes. Genes nominally differentially expressed compared to TD
51 specifically in ASD, but not Non-TD, significantly overlapped with seven high confidence
52 ASD genes. 218 transcripts in common to ASD and Non-TD differential expression
53 compared to TD were significantly enriched for functions in immune response to
54 interferon-gamma, apoptosis, and metal ion transport. WGCNA identified co-expressed
55 gene modules significantly correlated with 5-MeTHF, folic acid, DMG, and betaine. A
56 module enriched in DNA methylation functions showed a protective association with folic
57 acid/5-MeTHF concentrations and ASD risk. Independent of child outcome, maternal
58 plasma betaine and DMG concentrations associated with a block of co-expressed genes
59 enriched for adaptive immune, histone modification, and RNA processing functions.

60 **Limitations:** Blood contains a heterogeneous mixture of cell types, and many WGCNA
61 modules correlated with cell type and/or nutrient concentrations, but not child outcome.
62 Gestational age correlated with some co-expressed gene modules in addition to nutrients.

63 **Conclusions:** These results support the premise that the prenatal maternal blood
64 transcriptome is a sensitive indicator of gestational nutrition and children's later
65 neurodevelopmental outcomes.

66

67 **Keywords**

68 autism spectrum disorder, neurodevelopment, maternal blood, one-carbon metabolites,
69 nutrition, transcriptome, prenatal

70

71 **Background**

72 Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized
73 by persistent impairment in social interactions, communication, restricted interests or
74 repetitive behaviors, and sensory sensitivities [1]. Current data show that one in every 59
75 children in the United States has ASD [1]. One major component of ASD risk is genetic
76 heritability, based on studies of twins, siblings, and other family members [2–4]. Common
77 genetic variants each having small effects dominate most ASD risk compared with rare
78 gene variants with large effects [5]. Large genome-wide association studies (GWAS)
79 support the role of common genetic variants in ASD with remaining challenges in ASD
80 complexity and heterogeneity [6–8]. Mutations in single genes can only explain less than
81 1% of ASD cases [9,10].

82

83 Accumulating lines of evidence suggest that ASD risk arises from both genetic and
84 environmental risk factors. *In utero* maternal exposures can contribute as ASD risk factors,
85 including air pollution, fever, asthma, and nutrition, especially nutrients involved in the
86 one-carbon metabolic pathway [11–14]. Other studies suggest that one-carbon metabolism
87 is implicated in gene-environment interactions in ASD [15,16]. Maternal prenatal
88 nutritional supplements containing folic acid and additional B vitamins that play a role in
89 one-carbon metabolism are associated with an estimated 40% ASD risk reduction
90 [13,17,18].

91
92 Gene expression levels are also influenced by both genetic and environmental factors,
93 especially by *in utero* maternal nutrition [19,20]. Maternal peripheral blood therefore
94 offers a unique window to study transcriptome alterations during pregnancy that may
95 reflect altered fetal development associated with nutrition [21,22]. Numerous
96 environmental factors during pregnancy can alter gene expression levels [23,24]. Recent
97 studies of schizophrenia demonstrated a significant interaction of genetic risk with
98 maternal perinatal environmental factors that affected the transcriptome [25,26].
99 Postmortem brain gene expression studies showed gene co-expression was enriched at
100 immune response and neuronal development in ASD [27,28]. Other studies using child
101 peripheral blood and cord blood showed differential gene expression in ASD was enriched
102 for immune and inflammatory processes [29–31].

103
104 While numerous studies have investigated specific genes or pathways in children with ASD,
105 none have focused on the maternal transcriptome during pregnancy. Further, most
106 previous ASD transcriptome studies used data from specimens collected postmortem or
107 after childbirth, as opposed to prospective studies to help understand potential etiologic
108 changes that occur before behavior symptoms. Other large epidemiology studies examined
109 environmental effects in ASD, but how the environment influences alterations at the
110 molecular level remains to be understood. The goal of this study was to examine maternal
111 prenatal gene expression profiles associated with both maternal serum one-carbon
112 metabolites and the child's later autism diagnosis to shed light on molecular changes
113 during pregnancy.

114

115 **Materials and Methods**

116 *MARBLES study design*

117 The MARBLES study recruited mothers in Northern California with at least one child with
118 ASD who were pregnant or planning another pregnancy. A previous publication detailed
119 the study design of MARBLES [31,32]. In order to enroll into MARBLES, all five following
120 criteria needed to be met: (1) the fetus of interest has one or more first or second degree
121 relatives with ASD; (2) mother is 18 years or older; (3) mother is pregnant or able to
122 become pregnant; (4) mother is able to speak, read, and understand English and plans to
123 raise the child with English spoken at home; (5) mother lives within 2.5-hour drive
124 distance from Davis/Sacramento, California region. Due to a shared genetic background,
125 the next child has higher risk for ASD. Demographic, diet, environmental, and medical
126 information were collected by telephone interviews or questionnaires through the
127 pregnancy. Infants received standardized neurodevelopmental assessments from 6 months
128 until 3 years old [32]. At 3 years old, the child was assessed clinically using the gold
129 standard Autism Diagnostic Observation Schedule (ADOS) [33], the Autism Diagnostic
130 Interview – Revised (ADI-R) [34], and the Mullen Scales of Early Learning (MSEL) [35].
131 Based on a previously published algorithm using ADOS and MSEL scores [18,31],
132 participants were classified into three outcome groups including ASD, TD, and Non-TD
133 [36,37]. Children with ASD had scores over the ADOS cutoff and fit ASD DSM-5 criteria.
134 Children with Non-TD outcomes were defined as children with low MSEL scores (two or
135 more MSEL subscales with more than 1.5 standard deviations (SD) below averages or at
136 least one MSEL subscale more than 2 SD below average) and elevated ADOS scores.

137 Children with TD outcome had all MSEL scores within 2.0 SD and no more than one MSEL
138 subscale that is 1.5 SD below the normative mean and scores on the ADOS at least three
139 points lower than the ASD cutoff.

140

141 *RNA isolation and expression microarray*

142 Maternal peripheral blood was collected at study visits during all three trimesters of
143 pregnancy in PAXgene Blood RNA tubes with the RNA stabilization reagent (BD
144 Biosciences) and stored frozen at -80°C. The first timepoint was used for mothers who had
145 multiple blood draws (n = 12) during pregnancy. RNA was isolated using the PAXgene
146 Blood RNA Kit (Qiagen) according to the manufacturer's instructions. Total RNA was
147 converted to cDNA and biotin labeled. Expression was measured using Human Gene 2.0
148 Affymetrix microarray chips by the John Hopkins Sequencing and Microarray core
149 following washing, staining, and scanning procedures based on manufacture's protocol.

150

151 *Data preprocessing and normalization*

152 Robust Multi-Chip Average (RMA) [38–40] from the oligo R package was used for
153 normalization of Affymetrix CEL files. For quality control, we used the oligo and
154 ArrayQualityMetrics R packages [41,42]. No samples were identified as outliers by
155 principal component analysis, the Kolmogorov-Smirnov test, or distance to other arrays.
156 Probes were mapped at the transcript level using the pd.hugene.2.0.st R package, and those
157 annotated to genes (36,459) were used in subsequent analyses.

158

159 *One-carbon nutrient metabolite measurements*

160 Serum and plasma samples from the same blood draw as specimens used for RNA
161 expression analysis were used to measure one-carbon and nutrient metabolites. S-
162 adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH), adenosine, homocysteine,
163 cystine, cysteine, glutathione (GSH) and glutathione disulfide (GSSG) were measured in the
164 James' laboratory at the Arkansas Children's Research Institute using HPLC with
165 electrochemical detection as previously described [43,44]. Serum pyridoxal phosphate
166 (PLP), the biologically active form of vitamin B6 (Vit B6), was measured by HPLC using
167 fluorescence detection in the Green-Miller laboratory at the UC Davis Medical Center (inter-
168 assay CV = 4.8%) [45]. Total serum vitamin B12 (Vit B12) was measured using automated
169 chemiluminescence in the CLIA-approved Medicine Clinical Laboratories at UC Davis
170 Medical Center (inter-assay CV = 6.2%). Plasma choline, betaine and dimethylglycine
171 (DMG) were measured using LC-MS/MS stable isotope dilution methods in the Caudill
172 laboratory [46,47] with modifications to include measurements of trimethylamine N-oxide
173 (TMAO) and methionine [48,49]. Intra-assay and inter-assay CVs of the in-house controls
174 were 3.0% and 3.6% for choline; 1.5% and 1.7% for betaine, 2.5% and 2.4% for DMG; 2.6%
175 and 2.6% for methionine; and 3.1% and 3.4% for TMAO. Serum 5-methyltetrahydrofolate (5-
176 MeTHF) and folic acid were quantified in the Caudill laboratory using LC-MS/MS stable-
177 isotope dilution methods [50] with modifications based on the instrumentation [51]. Intra-
178 assay and inter-assay CVs of in-house controls were 1.8% and 1.9% for 5-
179 methyltetrahydrofolate; and 4.9 and 8.5% for folic acid.

180

181 *Differential gene expression*

182 After normalization, surrogate variable analysis (SVA) was used to estimate and adjust for
183 hidden cofounding variables on gene expression [52]. Differential gene expression was
184 identified using the limma R package by a linear model that included the children's
185 diagnosis outcome and all surrogate variables [53]. Differential gene expression analysis
186 with children diagnosed as ASD and children diagnosed as Non-TD were included in the
187 same model with three levels of diagnosis [53]. Fold change and standard error were
188 calculated using the limma R package. Differentially expressed transcripts were identified
189 as those with an unadjusted p -value < 0.05 . Genome-wide significant differentially
190 expressed transcripts were classified as those with a false discovery rate (FDR) adjusted p -
191 value (q -value) < 0.05 .

192

193 *Gene ontology (GO) term and pathway enrichment analysis*

194 Transcripts with significant expression levels or selected gene lists were exported to
195 DAVID bioinformatics software with default settings for GO analysis [54,55]. The analysis
196 was done using the GO ontology database and Fisher's exact test with multiple test
197 correction by the FDR method [55]. GO term enrichments were presented by hierarchical
198 terms. GO terms with an FDR q -value < 0.05 were considered statistically significant.

199

200 *Weighted Gene Co-Expression Network Analysis (WGCNA)*

201 A weighted gene co-expression network was built using the WGCNA R package [56,57] with
202 normalized expression levels after adjustment for batch effects using the ComBat function
203 from the sva R package [58]. The correlation matrix included all probes and all samples. To
204 construct a signed adjacency matrix, estimated soft thresholding power was used with

205 approximately scale-free topology (R^2 fit more than 0.8). Adjacency values were
206 transformed into a signed topological overlap matrix (TOM). Co-expression modules were
207 identified from a dissimilarity matrix (1-TOM) with a minimum module size of 30 probes.
208 Module eigengenes were clustered on correlation. Similar modules were merged based on
209 a cut height of 0.25 to generate co-expression modules. Each module's expression profile
210 was summarized into a module eigengene (ME) using the matched module's first principle
211 component. The correlation between each gene in the module with the ME was
212 represented as intramodule connectivity (kME). Module hub probes were defined as the
213 probe in each module with the highest module membership. Pearson's correlation
214 coefficient was used to measure the correlation between traits and modules.

215

216 *Cell type proportion deconvolution*

217 CIBERSORT was used to estimate the proportions of each cell type using the default
218 settings and the LM22 adult peripheral blood signature gene expression profiles [59].
219 Normalized expression levels adjusted for batch effects were used to estimate cell type
220 proportions. Both relative and absolute modes were performed together with 100
221 permutation tests. *P*-values were calculated using FDR multiple test adjustment. Significant
222 associations were defined based on FDR *q*-value < 0.05.

223

224 **Results**

225 *Study sample characteristics and nutrient measurements*

226 High quality RNA was isolated from 300 maternal peripheral blood samples collected
227 during pregnancy in the MARBLES high risk ASD cohort (**Supplementary Table 1**).

228 Children from MARBLES pregnancies were diagnosed at 3 years old as ASD (67, including
229 47 male and 20 female), Non-TD (79, including 46 male and 33 female), and TD (154,
230 including 79 male and 75 female) (**Table 1**).

231
232 Nutrients in the one-carbon metabolism pathway, including methionine, SAM, SAH,
233 adenosine, homocysteine, 5-MeTHF, folic acid, Vit B6, Vit B12, choline, DMG, betaine,
234 cystine, cysteine, GSH, and GSSG were directly measured from maternal blood in 14% -
235 62% of all collected samples (**Table 2**). None of these metabolites in maternal blood were
236 significantly associated with clinical outcomes of children (**Table 2**).

237
238 *Differential gene expression analyses by child outcome*

239 Expression was measured using Human Gene 2.0 Affymetrix microarray and adjusted for
240 surrogate variables, followed by differential gene expression analysis for child diagnosis
241 (ASD, Non-TD, TD) on 36,459 transcripts. There were 28 surrogate variables (SVs)
242 identified, including some significantly associated with batch effect and gestational age of
243 maternal blood draw (**Supplementary Fig. 1**). Six transcripts located at four genes (*TGR-*
244 *AS1*, *SQSTM1*, *HLA-C*, and *RFESD*) showed genome-wide significance with child outcomes
245 (FDR adjusted p -value < 0.05) (**Supplementary Table 2**). Three out of six transcripts
246 mapped to *HLA-C* (Major Histocompatibility Complex, Class I, C) (FDR adjusted p -value <
247 0.05). For those three *HLA-C* transcripts, increased levels were observed in ASD vs TD as
248 well as Non-TD vs TD (unadjusted p -value < 0.05) (**Supplementary Fig. 2**).

249

250 Comparing the maternal blood transcriptome between ASD and TD outcomes revealed
251 2,012 differentially expressed transcripts at a marginal confidence level (unadjusted p -
252 value < 0.05) that mapped to 1,912 genes, including 980 up-regulated and 1,032 down-
253 regulated transcripts, with none significant after FDR adjustment (**Fig. 1A, Supplementary**
254 **Table 3**). There was a significant overlap between these 1,912 differentially expressed
255 genes and a list of strong ASD candidate genes from the Simons Foundation Autism
256 Research Initiative (SFARI Gene, including *TRIO*, *GRIA1*, *SMARCC2*, *SPAST*, *DIP2C*, *FOXP1*,
257 *CNTN4*, Fisher's exact test, p -value < 0.05) [60].

258
259 Comparing the maternal blood transcriptome between Non-TD and TD outcomes revealed
260 1,987 differentially expressed transcripts at a marginal confidence level (unadjusted p -
261 value < 0.05) that mapped to 1,919 genes, including 1,044 up-regulated and 943 down-
262 regulated transcripts (**Fig. 1B, Supplementary Table 4**). Two of these transcripts at
263 *RFESD* and *TRG-AS1* genes also passed genome-wide significance (FDR adjusted p -value <
264 0.05). Unlike the ASD vs TD comparison, however, no significant overlap was observed
265 between Non-TD differentially expressed genes and SFARI gene lists.

266
267 A significant overlap of 218 transcripts was observed between ASD associated
268 differentially expressed transcripts and Non-TD associated differentially expressed
269 transcripts (Fisher's exact test, p -value < 2.2E-16) (**Fig. 1C**). Gene ontology (GO) analysis of
270 these 218 transcripts revealed significant enrichment for the interferon-gamma mediated
271 signaling pathway, apoptosis in muscle, response to interferon gamma, and metal ion
272 transport (**Fig. 1D, Supplementary Fig. 3**). CaMK (calmodulin-dependent protein kinase)

273 families (*CAMK2A*, *CAMK2B*, *CAMK2D* and *CAMK2G*) and HLA (human leukocyte antigen)
274 systems (*HLA-B*, *HLA-C* and *HLA-E*) were included in those pathways (**Fig. 1D**). In contrast,
275 neither list of ASD- or TD-specific differentially expressed transcripts were significantly
276 enriched for any GO terms.

277
278 *Weighted gene co-expression network analysis (WGCNA) identified gene modules correlating*
279 *with specific maternal nutrient levels*

280 WGCNA was performed as a complementary bioinformatic approach that incorporates the
281 independent and inter-related associations of transcript levels with measured
282 concentrations of maternal nutrients. First, expression values were adjusted for batch
283 effect, then correlation patterns among all transcripts were analyzed across all 300
284 samples. WGCNA identified 27 co-expressed gene modules in our dataset, representing
285 17,049 transcripts, distinguished from 19,410 transcripts not clustered and grouped into
286 the “grey” module (**Fig. 2A, Fig. 2B, Supplementary Fig. 4, Supplementary Table 5**). For
287 each module, the number of transcripts, as well as the hub gene, defined as the gene with
288 the highest correlation with the module eigengene, were determined (**Fig. 2B,**
289 **Supplementary Table 6**). Out of those 27 co-expression modules, 23 modules showed
290 associations between eigengene expression level and at least one variable related to
291 demographics, diagnosis, or maternal nutrients, after correction (FDR adjusted p -value <
292 0.05) (**Fig. 2A, Supplementary Fig. 4**). All 27 modules were significantly associated with
293 one or more covariates at unadjusted p -value < 0.05 (**Fig. 2A, Supplementary Fig. 5**).

294

295 Multiple co-expression modules were significantly correlated (FDR adjusted p -value <
296 0.05) with gestational age at blood draw and four maternal metabolites, including 5-
297 MeTHF, folic acid, DMG, and betaine (**Fig. 2A**). None of the additional measured variables
298 was associated with any co-expression gene modules at a high confidence level, including
299 clinical outcome. However, the module “greenyellow” showed a marginally significant
300 positive correlation with outcome (unadjusted p -value = 0.02, FDR adjusted p -value = 0.14)
301 and a negative significant correlation with both 5-MeTHF (FDR adjusted p -value = 0.02)
302 and folic acid levels (FDR adjusted p -value = 0.02) (**Fig. 2A, Fig. 3A, Fig. 3B,**
303 **Supplementary Fig. 4, Supplementary Fig. 5, Supplementary Table 7**). This
304 greenyellow module eigengene also showed opposite correlation between ASD and 5-
305 MeTHF, consistent with 5-MeTHF protective functions in ASD (**Fig. 3A, Fig. 3B**).
306
307 This “greenyellow” module contained 224 transcripts with *TRNAI2* as hub gene
308 (**Supplementary Table 7**). These 224 transcripts showed a significant enrichment for
309 gene ontology functions in methylation-CpG binding, methyl-dependent chromatin
310 silencing, and keratinocyte differentiation (Fisher’s exact test, FDR adjusted p -value < 0.05)
311 (**Fig. 3C, Supplementary Table 8**). The three known genes with methyl-binding functions
312 included *MBD3L3*, *MBD3L4* and *MBD3L5*, represented by 16857547, 16867905, and
313 16867910 transcripts (**Fig. 3C**). Normalized expression of those three transcripts was also
314 significantly associated with the “greenyellow” module eigengene, supporting their
315 membership in the module (**Fig. 3D**).
316
317 *Eight co-expression modules strongly clustered with betaine and DMG*

318 Among the 27 identified co-expression modules, eight modules (darkred, lightgreen, cyan,
319 darkgrey, brown, magenta, orange and white) were highly correlated with each other and
320 clustered based on unsupervised hierarchical clustering, representing a total of 2,582
321 transcripts (**Fig. 4, Supplementary Fig. 6, Supplementary Table 9**). Betaine and DMG
322 were significantly associated and clustered together with this distinct block of co-
323 expression modules.

324
325 Transcripts inside these eight clustered co-expression modules associated with betaine and
326 DMG showed significant enrichment for 18 gene pathways involved in adaptive immune
327 response, RNA processing, histone modification, inflammatory response, and Rett
328 syndrome (Fisher's exact test, FDR adjusted p -value < 0.05) (**Supplementary Fig. 7**).
329 Network analysis using GeneMANIA [61] identified a network with *EVL* in the center,
330 linked with other hub genes (**Supplementary Fig. 8**).

331
332 *Cell type composition in maternal peripheral blood associated with maternal metabolites but*
333 *not child clinical outcomes*

334 In order to determine the effects of cell composition differences on the findings associated
335 with maternal transcriptomes, cell type specific information from 22 immune cell types
336 was deconvoluted using the CIBERSORT web tool. Maternal peripheral blood samples
337 reflected a mixture of cell types, with neutrophils as the largest and most variable
338 population ranging from 17% to 48% (**Fig. 5A, Supplementary Table 10**). The eigengenes
339 for 21 out of 27 modules were significantly correlated with at least one cell type (FDR
340 adjusted p -value < 0.05) (**Supplementary Fig. 9**). No significant difference was observed in

341 cell type composition between child diagnosis outcomes or gender (**Fig. 5A. 5B,**
342 **Supplementary Fig. 10**). Furthermore, neither the “greenyellow” module, nor the betaine
343 and DMG variables were significantly associated with cell type proportions, suggesting that
344 the associations identified with these modules were largely cell type independent (**Fig. 5B,**
345 **Supplementary Fig. 9, Supplementary Fig. 10**).

346
347 In contrast, some cell type proportions were significantly correlated with some maternal
348 metabolites. Vit B6, 5-MeTHF, choline, cysteine, the ratio of DMG/betaine, and the ratio of
349 cystine/cysteine were separately associated with six cell types (FDR adjusted p -value <
350 0.05) (**Fig. 5B, Supplementary Fig. 10**). Vit B12, folic acid, the ratio of DMG/betaine, and
351 the ratio of SAM/SAH were associated with more than one cell type (FDR adjusted p -value
352 < 0.05) (**Fig. 5B, Supplementary Fig. 10**). The most significant association was between
353 vit B12 and memory B cells (FDR adjusted p -value = 0.0001) (**Fig. 5B, Supplementary Fig.**
354 **10**).

355

356 **Discussion**

357 Maternal blood collected during pregnancy provides molecular insights into the *in utero*
358 environment relevant to the etiology of ASD. This was the first study to our knowledge to
359 examine gene expression differences in maternal peripheral blood during pregnancy
360 together with *in utero* maternal one-carbon metabolites for children that went on to
361 develop ASD, TD, or Non-TD at 36 months. Using complementary bioinformatics
362 approaches, we identify several genes and gene pathways consistent with proinflammatory
363 and oxidative stress responses in mothers of children with adverse neurodevelopmental

364 outcomes. We also identify eight novel coregulated gene modules associated with maternal
365 blood betaine and DMG concentration.

366

367 *Genes and gene patterns common to mothers of children with ASD and non-typical*
368 *neurodevelopment*

369 Using differential gene expression analysis of individual genes, we describe four genes
370 (*SQSTM1*, *HLA-C*, *TRG-AS1*, *RFESD*) that were differentially expressed in mothers of TD
371 children compared with those diagnosed as either ASD or non-TD. *SQSTM1* encodes the
372 p62 sequestosome that acts as a receptor for ubiquitinated cargo in the selective autophagy
373 response induced by oxidative stress [62], and also links mTOR and GABA signaling
374 pathways in brain [63]. *RFESD*, encoding an iron-sulfur cluster binding protein with
375 oxidoreductase activity, is located on 5q15, a hotspot for copy number variants in
376 intellectual and developmental disabilities [64,65]. *TRG-AS1*, T-cell receptor gamma locus
377 antisense RNA 1, is located on 7p14.1, another locus previously associated with
378 developmental delay, intellectual disability, and ASD [64,66,67]. *HLA-C* belongs to the HLA
379 (human leukocyte antigen) polymorphic loci encoding major histocompatibility class I
380 (MHC I) proteins involved in antigen presentation to CD8+ T cells and NK cells. HLA-C is
381 important for both tolerance to fetal allo-antigens and viral immunity during pregnancy
382 [68]. Proinflammatory cytokines such as interferon gamma (IFN γ) induce HLA-C
383 expression in both lymphocytes and placental trophoblasts. A number of previous studies
384 have shown that the HLA locus is associated with ASD [69–71] or HLA locus activation in
385 ASD children and their mothers[72–74], which is consistent with our findings of elevated
386 *HLA-C* expression levels in ASD and Non-TD compared to TD mothers . Furthermore, two

387 additional class I loci, *HLA-B* and *HLA-E*, were also differentially expressed in mothers of
388 children classified as ASD and Non-TD compared to TD children in this study, providing
389 further evidence of an MHC I response in pregnancies of atypical neurodevelopment.

390
391 Furthermore, gene pathway analysis of differentially expressed genes common to
392 nontypical development revealed enrichment for the interferon-gamma mediated signaling
393 pathway, which has been previously found to be elevated in mothers of children with ASD
394 and other neurodevelopmental disorders [75,76]. In one such study, elevated interferon-
395 gamma levels in maternal midgestation peripheral blood was associated with a 50%
396 increased risk of offspring ASD risk [75]. A second enriched pathway included CaMK family
397 members which play an important role in neuronal connectivity and synaptic plasticity
398 [10,77,78] as well as immune response and inflammation [79]. Prior ASD studies have
399 implicated the CaMK pathway in the dendritic growth and local connectivity alterations
400 related to gene-environment interactions in ASD [10,77,78].

401
402 While genome-wide significance of individual differentially expressed genes was not
403 observed between samples from mothers whose children developed ASD compared to TD
404 after adjusting for multiple comparisons, seven genes with significant unadjusted *p* values
405 were also on the SFARI list of strong ASD candidate genes. *TRIO*, Trio Rho guanine
406 nucleotide exchange factor, promotes exchange of GDP for GTP and provides necessary
407 support for cell migration and cell growth related to Alzheimer disease and other types of
408 neurological conditions [80,81]. *GRIA1*, the predominant excitatory neurotransmitter in
409 brain, is associated with the activation of normal neurophysiologic processes [80,82].

410 *SMARCC2* encodes a chromatin remodeling protein with helicase and ATPase activities
411 which has been implicated in altering chromatin structure in ASD [83]. *CNTN4* functions in
412 neuronal network formation and plasticity, and is associated with nervous system
413 development at the transcriptome level [84,85]. Mutations in *FOXP1*, a developmental
414 transcription factor, are observed in rare cases of intellectual disability with ASD [86,87].
415
416 *Methylation and methyl-binding functions in a gene module oppositely associated with folic*
417 *acid and ASD risk*
418 The complementary co-expression network analysis further revealed a module of 224 co-
419 expressed genes in maternal blood showing an association with folic acid and 5-MeTHF
420 levels in the opposite direction from ASD risk that could not be explained by cell type
421 differences. Interestingly, these ASD and nutrient associated genes were functionally
422 enriched for DNA methylation binding and methylation-dependent chromatin silencing,
423 consistent with prior DNA methylation changes observed in ASD [88–91] as well as ASD-
424 like syndromes associated with methyl binding proteins [92,93]. Folic acid, the synthetic
425 form of folate that contributes substrate for one-carbon metabolism, and 5-MeTHF, one of
426 the active biological forms of folate that plays a critical role in one-carbon metabolism, have
427 also been shown to be inversely associated with developmental delay [14,15,94,95].
428 *MBD3L* is predicted to assist with demethylation reactions and functions as a
429 transcriptional repressor [96–98].
430
431 One-carbon metabolites associated with changes in gene expression in this study have also
432 been associated with prevention of numerous conditions [89,99–101]. The coregulated

433 block of betaine and DMG co-expression modules contained genes enriched in the adaptive
434 immune system and chromatin modification functions, as well as Rett syndrome, a known
435 syndromic form of ASD [102–105]. Choline can be metabolized to betaine, which converts
436 homocysteine to form methionine and generates DMG in the one-carbon pathway
437 [106,107]. A previous study of maternal peripheral blood collected at term showed that
438 changes of betaine and DMG were in the opposite direction from choline when compared
439 with nonpregnant women [108]. *EVL* (Enah/Vasp-like) is involved in actin cytoskeleton
440 remodeling and is crucial for central neuron system processes and immune system
441 functions [109–111]. One study also showed *EVL* as a differentially expressed gene in
442 schizophrenia in peripheral blood [110].

443
444 Previous studies in ASD have been focused on post mortem brain tissue [28,112], as a
445 tissue relevant to the disorder, but collected after diagnoses were made, raising concerns
446 about reverse causation in determining etiologically-relevant expression changes. Few
447 studies have focused on prospective transcriptomic profiles collected prior to the
448 presentation of the disorder [31,113], and none have examined maternal gene expression
449 profiles during pregnancies at high risk for developing ASD. In addition, few studies have
450 integrated maternal transcriptome and one-carbon metabolite data within biospecimens.
451 Furthermore, most studies of ASD expression biomarkers have not considered the roles of
452 nutritional factors during pregnancy that could be relevant to fetal development.

453

454 **Limitations**

455 A limitation of using maternal peripheral blood to examine expression is that it contains
456 multiple cell types, and proportions can differ across samples. However, estimated cell type
457 composition of maternal blood was not significantly associated with the child's clinical
458 outcomes, the "greenyellow" module, betaine, or DMG, which suggests that our main
459 findings were not driven by differential cell type proportions. After correcting for multiple
460 comparisons, this study did not identify any individual differentially maternally expressed
461 genes specifically associated with ASD, although 6 transcripts from 4 genes reached
462 genome-wide significance with diagnosis of either ASD or Non-TD. Furthermore, lack of
463 genome-wide evidence of individual differentially expressed genes specific to a pairwise
464 comparison of ASD vs. TD is likely due to the relatively small sample size that is inherent to
465 a prospective ASD study, but likely underpowered to detect small differences in transcript
466 levels. However, this does not eliminate the importance of identifying and understanding
467 the biologically significant gene set enrichments and co-expression network modules using
468 differential expression gene and WGCNA analysis. Additionally, other factors, including
469 genetics, epigenetics, and other environmental factors can influence the transcriptome and
470 ASD risk. Approaches incorporating those factors will be important in future studies.

471

472 **Conclusions**

473 In summary, genome-wide gene expression analysis of maternal peripheral blood samples
474 revealed transcriptome changes associated with maternal one-carbon metabolites and
475 child neurodevelopmental outcomes implicating maternal immune, apoptotic, and
476 epigenetic mechanisms in ASD. In addition, folic acid and 5-MeTHF were associated with
477 expression of genes involved in methylated-CpG binding in an opposite direction to that of

478 ASD, consistent with prior evidence of protection. Finally, maternal betaine and DMG levels
479 clustered with co-expressed genes related to immune, chromatin modification, and
480 development functions. These results therefore provide important biological insights into
481 maternal gene pathways associated with adverse neurodevelopment in the child, as well as
482 the protective role of one carbon metabolites in the complex etiology of ASD.

483

484 **List of abbreviations**

485 autism spectrum disorder (ASD), non-typical development (Non-TD), typical development
486 (TD), autism diagnostic observation schedule (ADOS), autism diagnostic interview –
487 revised (ADI-R), Markers of Autism Risk in Babies - Learning Early Signs (MARBLES),
488 weighted gene correlation network analysis (WGCNA), false discovery rate (FDR), standard
489 deviations (SD), surrogate variable analysis (SVA), gene ontology (GO), Simons Foundation
490 Autism Research Initiative (SFARI), 5'-methyltetrahydrofolate (5-MeTHF), dimethylglycine
491 (DMG), S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), glutathione (GSH),
492 glutathione disulfide (GSSG), vitamin B6 (Vit B6), vitamin B12 (Vit B12)

493

494 **Declarations**

495 *Ethics approval and consent to participate*

496 The UC Davis Institutional Review Board and the State of California Committee for the
497 Protection of Human Subjects approved this study and the MARBLES Study protocols. All
498 data and specimens were collected after parent given written informed consent form.

499

500 *Consent for publication*

501 Not applicable.

502

503 *Availability of data and material*

504 Data are shared in the Gene Expression Omnibus (GEO) accession number (GSE148450)

505 based on participant consent. Code and scripts for this study are available on GitHub

506 (<https://github.com/Yihui-Zhu/AutismMaternalBloodExpression>). Other related data and

507 information are included at supplementary tables.

508

509 *Competing interests*

510 The authors declare that there are no competing interests.

511

512 *Funding*

513 This work was supported by the National Institutes of Health (P01 ES011269, R01

514 ES029213, UG3 OD023365, U54HD079125)

515

516 *Authors' contributions*

517 YZ was the lead author and contributed substantially to all bioinformatics data analysis,

518 data visualization, interpretation of results, and writing the manuscript. CEM and BPD

519 added critical advice for bioinformatics data analysis methods and interpretation. MAC,

520 OVM, JWM, JSJ and SBM contributed to nutrient metabolite measurements. MDF, IH and RJS

521 contributed to study design, and subject acquisition, diagnosis and characterization. RJS

522 and JML conceived the study and contributed substantially to data interpretation and

523 revision of the manuscript. All authors read and approved the final manuscript.

524

525 *Acknowledgements*

526 We would like to thank the UCD Children's Center for Environmental Health for helpful
527 discussions and the MARBLES study participants. We would also like to thank Daniel Young
528 provided substantial assistance with multiple data sets data preparation.

529

530 **References**

- 531 1. Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J, Warren Z, et al. Prevalence of
532 Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental
533 Disabilities Monitoring Network, 11 Sites, United States, 2014. *MMWR Surveill Summ*.
534 2018;67:1–23.
- 535 2. Wessels WH, Pompe van Meerdervoort M. Monozygotic twins with early infantile autism.
536 A case report. *S Afr Med J*. 1979;55:955–7.
- 537 3. Sandin S, Lichtenstein P, Kuja-Halkola R, Larsson H, Hultman CM, Reichenberg A. The
538 familial risk of autism. *JAMA - J Am Med Assoc. American Medical Association*;
539 2014;311:1770–7.
- 540 4. Ozonoff S, Young GS, Carter A, Messinger D, Yirmiya N, Zwaigenbaum L, et al. Recurrence
541 risk for autism spectrum disorders: a Baby Siblings Research Consortium study. *Pediatrics*.
542 American Academy of Pediatrics; 2011;128:e488-95.
- 543 5. Weiner DJ, Wigdor EM, Ripke S, Walters RK, Kosmicki JA, Grove J, et al. Polygenic
544 transmission disequilibrium confirms that common and rare variation act additively to
545 create risk for autism spectrum disorders. *Nat Genet. Nature Publishing Group*;
546 2017;49:978–85.

- 547 6. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of
548 common genetic risk variants for autism spectrum disorder. *Nat Genet.* 2019;
- 549 7. Sanders SJ, He X, Willsey AJ, Ercan-Sencicek AG, Samocha KE, Cicek AE, et al. Insights into
550 Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci. *Neuron.*
551 NIH Public Access; 2015;87:1215–33.
- 552 8. Iossifov I, O’Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The contribution of
553 de novo coding mutations to autism spectrum disorder. *Nature.* Nature Publishing Group;
554 2014;515:216–21.
- 555 9. Tsai PC, Bell JT. Power and sample size estimation for epigenome-wide association scans
556 to detect differential DNA methylation. *Int J Epidemiol.* 2015;44:1429–41.
- 557 10. Bourgeron T. From the genetic architecture to synaptic plasticity in autism spectrum
558 disorder. *Nat Rev Neurosci.* 2015;16:551–63.
- 559 11. Raz R, Roberts AL, Lyall K, Hart JE, Just AC, Laden F, et al. Autism spectrum disorder and
560 particulate matter air pollution before, during, and after pregnancy: A nested case–control
561 analysis within the nurses’ health study II cohort. *Environ Health Perspect.* 2015;
- 562 12. Zerbo O, Iosif A-M, Walker C, Ozonoff S, Hansen RL, Hertz-Picciotto I. Is Maternal
563 Influenza or Fever During Pregnancy Associated with Autism or Developmental Delays?
564 Results from the CHARGE (CHildhood Autism Risks from Genetics and Environment) Study.
565 *J Autism Dev Disord.* Springer US; 2013;43:25–33.
- 566 13. Schmidt RJ, Hansen RL, Hartiala J, Allayee H, Schmidt LC, Tancredi DJ, et al. Prenatal
567 vitamins, one-carbon metabolism gene variants, and risk for autism. *Epidemiology.* NIH
568 Public Access; 2011;22:476–85.
- 569 14. Schmidt RJ, Tancredi DJ, Ozonoff S, Hansen RL, Hartiala J, Allayee H, et al. Maternal

- 570 periconceptional folic acid intake and risk of autism spectrum disorders and
571 developmental delay in the CHARGE (Childhood Autism Risks from Genetics and
572 Environment) case-control study. *Am J Clin Nutr.* Oxford University Press; 2012; 96:80–9.
- 573 15. Schaevitz LR, Berger-Sweeney JE. Gene-Environment Interactions and Epigenetic
574 Pathways in Autism: The Importance of One-Carbon Metabolism. *ILAR J.* 2012;
- 575 16. Schaevitz L, Berger-Sweeney J, Ricceri L. One-carbon metabolism in
576 neurodevelopmental disorders: Using broad-based nutraceuticals to treat cognitive deficits
577 in complex spectrum disorders. *Neurosci. Biobehav. Rev.* 2014.
- 578 17. Suren P, Roth C, Bresnahan M, Haugen M, Hornig M, Hirtz D, et al. Association between
579 maternal use of folic acid supplements and risk of autism spectrum disorders in children. *J*
580 *Am Med Assoc.* 2013;309:570–7.
- 581 18. Schmidt RJ, Iosif A-M, Guerrero Angel E, Ozonoff S. Association of Maternal Prenatal
582 Vitamin Use With Risk for Autism Spectrum Disorder Recurrence in Young Siblings. *JAMA*
583 *Psychiatry.* American Medical Association;2019; 76:391.
- 584 19. Vucetic Z, Kimmel J, Totoki K, Hollenbeck E, Reyes TM. Maternal high-fat diet alters
585 methylation and gene expression of dopamine and opioid-related genes. *Endocrinology.*
586 2010;
- 587 20. Yajnik CS, Deshmukh US. Fetal programming: Maternal nutrition and role of one-carbon
588 metabolism. *Rev Endocr Metab Disord.* 2012;13:121–7.
- 589 21. Costello PM, Rowlerson A, Astaman NA, Anthony FEW, Sayer AA, Cooper C, et al. Peri-
590 implantation and late gestation maternal undernutrition differentially affect fetal sheep
591 skeletal muscle development. *J Physiol.* 2008;
- 592 22. Croen LA, Goines P, Braunschweig D, Yolken R, Yoshida CK, Grether JK, et al. Brain-

593 derived neurotrophic factor and autism: Maternal and infant peripheral blood levels in the
594 early markers for autism (EMA) study. *Autism Res.* 2008;
595 23. Haugen AC, Schug TT, Collman G, Heindel JJ. Evolution of DOHaD: The impact of
596 environmental health sciences. *J. Dev. Orig. Health Dis.* 2015.
597 24. Zerbo O, Iosif AM, Walker C, Ozonoff S, Hansen RL, Hertz-Picciotto I. Is Maternal
598 Influenza or Fever during Pregnancy Associated with Autism or Developmental Delays?
599 Results from the CHARGE (childhood Autism Risks from Genetics and Environment) Study.
600 *J Autism Dev Disord.* 2013;
601 25. Ursini G, Punzi G, Chen Q, Marengo S, Robinson JF, Porcelli A, et al. Convergence of
602 placenta biology and genetic risk for schizophrenia. *Nat Med.* Nature Publishing Group;
603 2018;24:792–801.
604 26. Xu J, He G, Zhu J, Zhou X, Clair DS, Wang T, et al. Prenatal nutritional deficiency
605 reprogrammed postnatal gene expression in mammal brains: Implications for
606 schizophrenia. *Int J Neuropsychopharmacol.* 2014;
607 27. Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J, et al. Transcriptome analysis
608 reveals dysregulation of innate immune response genes and neuronal activity-dependent
609 genes in autism. *Nat Commun.* Nature Publishing Group; 2014;5:5748.
610 28. Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, et al. Transcriptomic
611 analysis of autistic brain reveals convergent molecular pathology. *Nature.* Nature
612 Publishing Group; 2011;474:380–4.
613 29. Tylee DS, Hess JL, Quinn TP, Barve R, Huang H, Zhang-James Y, et al. Blood
614 transcriptomic comparison of individuals with and without autism spectrum disorder: A
615 combined-samples mega-analysis. *Am J Med Genet Part B Neuropsychiatr Genet.* 2017;

- 616 30. Ansel A, Rosenzweig JP, Zisman PD, Melamed M, Gesundheit B. Variation in gene
617 expression in autism spectrum disorders: An extensive review of transcriptomic studies.
618 Front. Neurosci. 2017.
- 619 31. Mordaunt CE, Park BY, Bakulski KM, Feinberg JI, Croen LA, Ladd-Acosta C, et al. A meta-
620 analysis of two high-risk prospective cohort studies reveals autism-specific transcriptional
621 changes to chromatin, autoimmune, and environmental response genes in umbilical cord
622 blood. Mol Autism. 2019;
- 623 32. Hertz-Picciotto I, Schmidt RJ, Walker CK, Bennett DH, Oliver M, Shedd-Wise KM, et al. A
624 Prospective Study of Environmental Exposures and Early Biomarkers in Autism Spectrum
625 Disorder: Design, Protocols, and Preliminary Data from the MARBLES Study. Environ
626 Health Perspect. Environmental Health Perspectives; 2018;126:117004.
- 627 33. Lord C, Risi S, Lambrecht L, Cook EH, Leventhal BL, DiLavore PC, et al. Autism
628 Diagnostic Observation Schedule (ADOS). J Autism Dev Disord. 2000;30:205–23.
- 629 34. Rutter M, LeCouteur A, Lord C. Autism Diagnostic Interview - Revised (ADI-R). Statew
630 Agric L Use Baseline 2015. 2015;1.
- 631 35. Mullen E. Mullen scales of early learning. 1995.
- 632 36. Chawarska K, Shic F, Macari S, Campbell DJ, Brian J, Landa R, et al. 18-month predictors
633 of later outcomes in younger siblings of children with autism spectrum disorder: a baby
634 siblings research consortium study. J Am Acad Child Adolesc Psychiatry. NIH Public Access;
635 2014 ;53:1317-1327.e1.
- 636 37. Ozonoff S, Young GS, Belding A, Hill M, Hill A, Hutman T, et al. The broader autism
637 phenotype in infancy: When does it emerge? J Am Acad Child Adolesc Psychiatry. 2014;53.
- 638 38. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix

- 639 GeneChip probe level data. *Nucleic Acids Res.* Oxford University Press; 2003;31:e15.
- 640 39. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods
641 for high density oligonucleotide array data based on variance and bias. *Bioinformatics.*
642 2003;19:185–93.
- 643 40. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al.
644 Exploration, normalization, and summaries of high density oligonucleotide array probe
645 level data. *Biostatistics.* 2003;4:249–64.
- 646 41. Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing.
647 *Bioinformatics.* 2010;26:2363–7.
- 648 42. Kauffmann A, Gentleman R, Huber W. arrayQualityMetrics—a bioconductor package for
649 quality assessment of microarray data. *Bioinformatics.* 2009;25:415–6.
- 650 43. Hollowood K, Melnyk S, Pavliv O, Evans T, Sides A, Schmidt RJ, et al. Maternal metabolic
651 profile predicts high or low risk of an autism pregnancy outcome. *Res Autism Spectr*
652 *Disord.* Elsevier Ltd; 2018;56:72–82.
- 653 44. Melnyk S, Fuchs GJ, Schulz E, Lopez M, Kahler SG, Fussell JJ, et al. Metabolic imbalance
654 associated with methylation dysregulation and oxidative damage in children with autism. *J*
655 *Autism Dev Disord.* 2012;42:367–77.
- 656 45. Talwar D, Quasim T, McMillan DC, Kinsella J, Williamson C, O’Reilly DSJ. Optimisation
657 and validation of a sensitive high-performance liquid chromatography assay for routine
658 measurement of pyridoxal 5-phosphate in human plasma and red cells using pre-column
659 semicarbazide derivatisation. *J Chromatogr B Anal Technol Biomed Life Sci.* 2003;
- 660 46. Holm PI, Ueland PM, Kvalheim G, Lien EA. Determination of choline, betaine, and
661 dimethylglycine in plasma by a high-throughput method based on normal-phase

662 chromatography-tandem mass spectrometry. *Clin Chem*. 2003;

663 47. Yan J, Wang W, Gregory JF, Malysheva O, Brenna JT, Stabler SP, et al. MTHFR C677T
664 genotype influences the isotopic enrichment of one-carbon metabolites in folate-
665 compromised men consuming d9-choline. *Am J Clin Nutr*. 2011;

666 48. Wang Y, Wang T, Shi X, Wan D, Zhang P, He X, et al. Analysis of acetylcholine, choline
667 and butyrobetaine in human liver tissues by hydrophilic interaction liquid
668 chromatography-tandem mass spectrometry. *J Pharm Biomed Anal*. 2008;

669 49. Yan J, Jiang X, West AA, Perry CA, Malysheva O V., Devapatla S, et al. Maternal choline
670 intake modulates maternal and fetal biomarkers of choline metabolism in humans. *Am J*
671 *Clin Nutr*. 2012;

672 50. Pfeiffer CM, Fazili Z, McCoy L, Zhang M, Gunter EW. Determination of Folate Vitamers in
673 Human Serum by Stable-Isotope-Dilution Tandem Mass Spectrometry and Comparison
674 with Radioassay and Microbiologic Assay. *Clin Chem*. 2004;

675 51. West AA, Yan J, Perry CA, Jiang X, Malysheva O V., Caudill MA. Folate-status response to
676 a controlled folate intake in nonpregnant, pregnant, and lactating women. *Am J Clin Nutr*.
677 2012;

678 52. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The SVA package for removing
679 batch effects and other unwanted variation in high-throughput experiments.
680 *Bioinformatics*. 2012;

681 53. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
682 expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res*. 2015;

683 54. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene Ontology:
684 tool for the unification of biology. *Nat Genet*. 2000;25:25–9.

- 685 55. The Gene Ontology Consortium. Expansion of the Gene Ontology knowledgebase and
686 resources. *Nucleic Acids Res.* 2017;45:D331–8.
- 687 56. Zhang B, Horvath S. A General Framework for Weighted Gene Co-Expression Network
688 Analysis. *Stat Appl Genet Mol Biol.* De Gruyter; 2005;4.
- 689 57. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network
690 analysis. *BMC Bioinformatics.* BioMed Central; 2008;9:559.
- 691 58. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data
692 using empirical Bayes methods. *Biostatistics.* 2007;
- 693 59. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of
694 cell subsets from tissue expression profiles. *Nat Methods.* Nature Publishing Group;
695 2015;12:453–7.
- 696 60. Abrahams BS, Arking DE, Campbell DB, Mefford HC, Morrow EM, Weiss LA, et al. SFARI
697 Gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs).
698 *Mol Autism.* BioMed Central; 2013;4:36.
- 699 61. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The
700 GeneMANIA prediction server: Biological network integration for gene prioritization and
701 predicting gene function. *Nucleic Acids Res.* 2010;
- 702 62. Sánchez-Martín P, Komatsu M. Physiological Stress Response by Selective Autophagy. *J*
703 *Mol Biol.* Academic Press; 2020;432:53–62.
- 704 63. Hui KK, Tanaka M. Autophagy links MTOR and GABA signaling in the brain. *Autophagy.*
705 2019.
- 706 64. Kaminsky EB, Kaul V, Paschall J, Church DM, Bunke B, Kunig D, et al. An evidence-based
707 approach to establish the functional and clinical significance of copy number variants in

- 708 intellectual and developmental disabilities. *Genet Med.* 2011;13:777–84.
- 709 65. Sajan SA, Fernandez L, Nieh SE, Rider E, Bukshpun P, Wakahiro M, et al. Both Rare and
710 De Novo Copy Number Variants Are Prevalent in Agenesis of the Corpus Callosum but Not
711 in Cerebellar Hypoplasia or Polymicrogyria. *PLoS Genet.* 2013;9.
- 712 66. Klamt J, Hofmann A, Böhmer AC, Hoebel AK, Gözl L, Becker J, et al. Further evidence for
713 deletions in 7p14.1 contributing to nonsyndromic cleft lip with or without cleft palate.
714 *Birth Defects Res Part A - Clin Mol Teratol.* 2016;
- 715 67. Wenger TL, Kao C, McDonald-McGinn DM, Zackai EH, Bailey A, Schultz RT, et al. The Role
716 of mGluR Copy Number Variation in Genetic and Environmental Forms of Syndromic
717 Autism Spectrum Disorder. *Sci Rep.* 2016;
- 718 68. Papúchová H, Meissner TB, Li Q, Strominger JL, Tilburgs T. The Dual Role of HLA-C in
719 Tolerance and Immunity at the Maternal-Fetal Interface. *Front. Immunol. Frontiers Media*
720 *S.A.*; 2019. p. 2730.
- 721 69. Torres AR, Maciulis A, Stubbs EG, Cutler A, Odell D. The transmission disequilibrium
722 test suggests that HLA-DR4 and DR13 are linked to autism spectrum disorder. *Hum*
723 *Immunol.* 2002;
- 724 70. Torres AR, Sweeten TL, Cutler A, Bedke BJ, Fillmore M, Stubbs EG, et al. The Association
725 and Linkage of the HLA-A2 Class I Allele with Autism. *Hum. Immunol.* 2006.
- 726 71. Saresella M, Marventano I, Guerini FR, Mancuso R, Ceresa L, Zanzottera M, et al. An
727 Autistic Endophenotype Results in Complex Immune Dysfunction in Healthy Siblings of
728 Autistic Children. *Biol Psychiatry.* 2009;
- 729 72. Guerini FR, Bolognesi E, Manca S, Sotgiu S, Zanzottera M, Agliardi C, et al. Family-based
730 transmission analysis of HLA genetic markers in Sardinian children with autistic spectrum

731 disorders. *Hum Immunol.* 2009;

732 73. Torres AR, Westover JB, Gibbons C, Johnson RC, Ward DC. Activating killer-cell
733 immunoglobulin-like receptors (KIR) and their cognate HLA ligands are significantly
734 increased in autism. *Brain Behav Immun.* 2012;

735 74. Guerini FR, Bolognesi E, Chiappedi M, Manca S, Ghezzi A, Agliardi C, et al. Activating KIR
736 molecules and their cognate ligands prevail in children with a diagnosis of ASD and in their
737 mothers. *Brain Behav Immun.* 2014;

738 75. Goines PE, Croen LA, Braunschweig D, Yoshida CK, Grether J, Hansen R, et al. Increased
739 midgestational IFN- γ , IL-4 and IL-5 in women bearing a child with autism: A case-control
740 study. *Mol Autism.* 2011;

741 76. Krakowiak P, Goines PE, Tancredi DJ, Ashwood P, Hansen RL, Hertz-Picciotto I, et al.
742 Neonatal Cytokine Profiles Associated With Autism Spectrum Disorder. *Biol Psychiatry.*
743 2017;

744 77. Zimmerman AW, Pessah IN, Lein PJ. Evidence for Environmental Susceptibility in
745 Autism. *Autism.* Humana Press; 2008. p. 409–28.

746 78. Stamou M, Streifel KM, Goines PE, Lein PJ. Neuronal connectivity as a convergent target
747 of gene \times environment interactions that confer risk for Autism Spectrum Disorders.
748 *Neurotoxicol. Teratol.* 2013. p. 3–16.

749 79. Racioppi L, Means AR. Calcium/calmodulin-dependent kinase IV in immune and
750 inflammatory responses: novel routes for an ancient traveller. *Trends Immunol.* Elsevier;
751 2008. p. 600–7.

752 80. De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. Synaptic,
753 transcriptional and chromatin genes disrupted in autism. *Nature.* 2014;

- 754 81. Katrancha SM, Wu Y, Zhu M, Eipper BA, Koleske AJ, Mains RE. Neurodevelopmental
755 disease-associated de novo mutations and rare sequence variants affect TRIO GDP/GTP
756 exchange factor activity. *Hum Mol Genet.* 2017;26:4728–40.
- 757 82. Geisheker MR, Heymann G, Wang T, Coe BP, Turner TN, Stessman HAF, et al. Hotspots of
758 missense mutation identify neurodevelopmental disorder genes and functional domains.
759 *Nat Neurosci.* 2017;
- 760 83. Devlin B, Boone BE, Levy SE, Lihm J, Buxbaum JD, Wu Y, et al. Patterns and rates of
761 exonic de novo mutations in autism spectrum disorders. *Nature.* 2012.
- 762 84. Yoshihara Y, Kawasaki M, Tamada A, Nagata S, Kagamiyama H, Mori K. Overlapping and
763 differential expression of BIG-2, BIG-1, TAG-1, and F3: Four members of an axon-associated
764 cell adhesion molecule subgroup of the immunoglobulin superfamily. *J Neurobiol.* 1995;
- 765 85. Fernandez T, Morgan T, Davis N, Klin A, Morris A, Farhi A, et al. Disruption of contactin
766 4 (CNTN4) results in developmental delay and other features of 3p deletion syndrome. *Am*
767 *J Hum Genet.* 2004;
- 768 86. Ferland RJ, Cherry TJ, Preware PO, Morrisey EE, Walsh CA. Characterization of Foxp2
769 and Foxp1 mRNA and protein in the developing and mature brain. *J Comp Neurol.* 2003;
- 770 87. Teramitsu I, Kudo LC, London SE, Geschwind DH, White SA. Parallel FoxP1 and FoxP2
771 Expression in Songbird and Human Brain Predicts Functional Interaction. *J Neurosci.* 2004;
- 772 88. Vogel Ciernia A, Laufer BI, Hwang H, Dunaway KW, Mordaunt CE, Coulson RL, et al.
773 Epigenomic Convergence of Neural-Immune Risk Factors in Neurodevelopmental Disorder
774 Cortex. *Cereb Cortex.* 2019;
- 775 89. Zhu Y, Mordaunt CE, Yasui DH, Marathe R, Coulson RL, Dunaway KW, et al. Placental
776 DNA methylation levels at CYP2E1 and IRS2 are associated with child outcome in a

- 777 prospective autism study. *Hum Mol Genet*. Narnia; 2019;28:2659–74.
- 778 90. Coulson RL, Yasui DH, Dunaway K, Laufer BI, Vogel Ciernia A, Zhu Y, et al. Snord116-
779 dependent diurnal rhythm of DNA methylation in mouse cortex. *Nat Commun*. Springer US;
780 2018;1–11.
- 781 91. Mordaunt CE, Jianu JM, Laufer B, Zhu Y, Dunaway KW, Bakulski KM, et al. Cord blood
782 DNA methylome in newborns later diagnosed with autism spectrum disorder reflects early
783 dysregulation of neurodevelopmental and X-linked genes. *bioRxiv*. Cold Spring Harbor
784 Laboratory; 2019;850529.
- 785 92. Cukier HN, Lee JM, Ma D, Young JI, Mayo V, Butler BL, et al. The Expanding Role of MBD
786 Genes in Autism: Identification of a MECP2 Duplication and Novel Alterations in MBD5,
787 MBD6, and SETDB1. *Autism Res*. 2012;5:385–97.
- 788 93. Cukier HN, Rabionet R, Konidari I, Rayner-Evans MY, Baltos ML, Wright HH, et al. Novel
789 variants identified in methyl-CpG-binding domain genes in autistic individuals.
790 *Neurogenetics*. Springer Verlag; 2010;11:291–303.
- 791 94. Scaglione F, Panzavolta G. Folate, folic acid and 5-methyltetrahydrofolate are not the
792 same thing. *Xenobiotica*. Informa Healthcare; 2014. p. 480–8.
- 793 95. Moretti P, Sahoo T, Hyland K, Bottiglieri T, Peters S, Del Gaudio D, et al. Cerebral folate
794 deficiency with developmental delay, autism, and response to folinic acid. *Neurology*.
795 Lippincott Williams and Wilkins; 2005;64:1088–90.
- 796 96. Mungall AJ. Meeting review: Epigenetics in development and disease. *Comp Funct*
797 *Genomics*. 2002. p. 277–81.
- 798 97. Fouse SD, Nagarajan RP, Costello JF. Genome-scale DNA methylation analysis.
799 *Epigenomics*. 2010. p. 105–17.

- 800 98. Zhou C, Wang Y, Zhang J, Su J, An Q, Liu X, et al. H3K27me3 is an epigenetic barrier while
801 KDM6A overexpression improves nuclear reprogramming efficiency. *FASEB J*. FASEB;
802 2019;33:4638–52.
- 803 99. Waterland RA, Jirtle RL. Early nutrition, epigenetic changes at transposons and
804 imprinted genes, and enhanced susceptibility to adult chronic diseases. *Nutrition*. 2004;
- 805 100. Afman L, Müller M. Nutrigenomics: From molecular nutrition to prevention of disease.
806 *J Am Diet Assoc*. 2006;
- 807 101. Mordaunt CE, Kieffer DA, Shibata NM, Członkowska A, Litwin T, Weiss K-H, et al.
808 Epigenomic signatures in liver and blood of Wilson disease patients include
809 hypermethylation of liver-specific enhancers. *Epigenetics Chromatin*. BioMed Central;
810 2019;12:10.
- 811 102. Amir RE, Van Den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is
812 caused by mutations in X-linked MECP2, encoding methyl- CpG-binding protein 2. *Nat*
813 *Genet*. Nature Publishing Group; 1999;23:185–8.
- 814 103. Craig SAS. Betaine in human nutrition. *Am. J. Clin. Nutr*. 2004.
- 815 104. Ducker GS, Rabinowitz JD. One-Carbon Metabolism in Health and Disease. *Cell Metab*.
816 2017.
- 817 105. Paparo L, Di Costanzo M, Di Scala C, Cosenza L, Leone L, Nocerino R, et al. The
818 influence of early life nutrition on epigenetic regulatory mechanisms of the immune
819 system. *Nutrients*. 2014;
- 820 106. Zeisel SH, Blusztajn JK. Choline and Human Nutrition. *Annu Rev Nutr*. 1994;
- 821 107. Ueland PM, Holm PI, Hustad S. Betaine: A key modulator of one-carbon metabolism
822 and homocysteine status. *Clin. Chem. Lab. Med*. 2005.

- 823 108. Friesen RW, Novak EM, Hasman D, Innis SM. Relationship of Dimethylglycine, Choline,
824 and Betaine with Oxoproline in Plasma of Pregnant Women and Their Newborn Infants. J
825 Nutr. 2007;
- 826 109. Krause M, Dent EW, Bear JE, Loureiro JJ, Gertler FB. Ena/VASP Proteins: Regulators of
827 the Actin Cytoskeleton and Cell Migration. Annu Rev Cell Dev Biol. 2003;
- 828 110. Gardiner EJ, Cairns MJ, Liu B, Beveridge NJ, Carr V, Kelly B, et al. Gene expression
829 analysis reveals schizophrenia-associated dysregulation of immune pathways in peripheral
830 blood mononuclear cells. J Psychiatr Res. 2013;
- 831 111. Tsunoda F, Lamon-Fava S, Asztalos BF, Iyer LK, Richardson K, Schaefer EJ. Effects of
832 oral eicosapentaenoic acid versus docosahexaenoic acid on human peripheral blood
833 mononuclear cell gene expression. Atherosclerosis. 2015;
- 834 112. Ginsberg MR, Rubin RA, Falcone T, Ting AH, Natowicz MR. Brain Transcriptional and
835 Epigenetic Associations with Autism. PLoS One. 2012;
- 836 113. Glatt SJ, Tsuang MT, Winn M, Chandler SD, Collins M, Lopez L, et al. Blood-based gene
837 expression signatures of infants and toddlers with autism. J Am Acad Child Adolesc
838 Psychiatry. 2012;

839

840 **Tables**

841 **Table 1. Demographic characteristics of mother participants and their children in**
842 **MARBLES, stratified by child diagnosis outcomes.**

	Children 36 Month Diagnosis			
	ASD (n = 67)	Non-TD (n = 79)	TD (n = 154)	p- value
Child male gender, n (%)	47 (70)	46 (58)	79 (51)	0.034

Maternal blood draw trimester during pregnancy, n (%)				0.240
Trimester 1	19 (28)	23 (29)	30 (19)	
Trimester 2	15 (22)	24 (30)	52 (34)	
Trimester 3	33 (49)	32 (41)	72 (47)	
HomeOwn	38 (59)	47 (60)	97 (64)	0.738
Gestational age of maternal blood draw (days), mean (SD)	165.87 (77.92)	162.65 (72.22)	174.21 (67.47)	0.949
Maternal age (years), mean (SD)	35.32 (5.07)	34.20 (4.12)	33.97 (4.73)	0.139
Maternal bachelor's degree +, n (%)	32 (48)	41 (52)	98 (64)	0.063
Maternal Smoke Pre-Pregnancy +, n (%)	5 (8)	6 (8)	4 (3)	0.120
Maternal weight before pregnancy (kg), mean (SD)	75.13 (23.18)	74.42 (22.36)	69.75 (16.75)	0.783
Maternal race and ethnicity, n (%)				0.061
White	50 (75)	53 (67)	128 (83)	
Black/African-American	4 (6)	5 (6)	4 (3)	
Asian	8 (12)	18 (23)	18 (12)	
Others	5 (7)	3 (4)	4 (3)	

843 ASD: Autism Spectrum Disorder; TD: Typical development; Non-TD: Non-typical
 844 development. *p*-values from Fisher's exact test for categorical variables and one-way
 845 ANOVA for continuous variables.

846

847 **Table 2. Descriptive statistics of maternal peripheral blood nutrients level in**

848 **MARBLES, stratified by children diagnosis.**

Maternal Metabolites	Children 36 Month Diagnosis				<i>p</i> -value
	ASD (n = 67)	Non-TD (n = 79)	TD (n = 154)	Total (n =300)	
Methionine (nM/ml), mean (SD)	21.89 (5.04)	22.52 (4.44)	21.5 (4.33)		0.448
n (%)	47 (70)	49 (62)	91 (59)	187 (62)	
SAM (nM/ml), mean (SD)	52.99 (9.87)	52.26 (9.13)	53.44 (9.68)		0.787
n (%)	47 (70)	49 (62)	90 (58)	186 (62)	
SAH (nM/ml), mean (SD)	26.99 (4.35)	25.92 (4.1)	25.85 (3.52)		0.240
n (%)	47 (70)	49 (62)	90 (58)	186 (62)	


ratio (SAM/SAH), mean (SD) n (%)	2.01 (0.49) 47 (70)	2.06 (0.5) 49 (62)	2.11 (0.49) 90 (58)	186 (62)	0.547
Adenosine (nM/ml), mean (SD) n (%)	0.25 (0.04) 47 (70)	0.24 (0.05) 49 (62)	0.24 (0.05) 90 (58)	186 (62)	0.379
Homocysteine (nM/ml), mean (SD) n (%)	8.72 (1.71) 47 (70)	8.91 (2.05) 49 (62)	8.56 (1.69) 90 (58)	186 (62)	0.562
5- Methyltetrahydrofolat e (nM/ml), mean (SD) n (%)	30.11 (5.26) 14 (20)	29.56 (10.16) 12 (15)	26.49 (5.67) 15 (10)	41 (14)	0.353
Folic acid (ng/ml), mean (SD) n (%)	1.06 (1.33) 14 (20)	1.23 (1.64) 12 (15)	2.77 (6.91) 15 (10)	41 (14)	0.518
Vitamin B6 (pg/ml), mean (SD) n (%)	116.09 (161.96) 18 (27)	62.83 (45.88) 14 (18)	62.83 (45.88) 37 (24)	69 (23)	0.350
Vitamin B12 (pg/ml), mean (SD) n (%)	320.25 (117.39) 16 (24)	350.25 (98.8) 12 (15)	347.13 (163.84) 23 (15)	51 (17)	0.796
Choline (nM/ml), mean (SD) n (%)	7.94 (2.96) 27 (40)	8.74 (2.12) 22 (28)	8.68 (1.99) 45 (30)	94 (31)	0.367
DMG (nM/ml), mean (SD) n (%)	1.53 (0.88) 27 (40)	1.4 (0.49) 22 (28)	1.35 (0.92) 45 (30)	94 (31)	0.685
Betaine (nM/ml), mean (SD) n (%)	15.52 (7.89) 27 (40)	14.53 (6.47) 22 (28)	12.85 (6.18) 45 (30)	94 (31)	0.253
ratio (DMG/Choline), mean (SD) n (%)	0.2 (0.15) 27(40)	0.17 (0.06) 22 (28)	0.16 (0.15) 45 (29)	94 (31)	0.522
ratio (DMG/Betaine), mean (SD) n (%)	0.11 (0.05) 27 (40)	0.11 (0.04) 22 (28)	0.11 (0.04) 45 (29)	94 (31)	0.998
Cystine (nM/ml), mean (SD) n (%)	26.6 (3.9) 34 (50)	26.06 (3.54) 41 (52)	26.04 (3.98) 58 (38)	133 (44)	0.769
Cysteine (nM/ml), mean (SD)	23.32 (3.42)	22.73 (2.96)	22.14 (2.92)		0.200

n (%)	34 (50)	41 (52)	58 (38)	133 (44)	
ratio (Cystine/Cysteine), mean (SD)	1.15 (0.16)	1.16 (0.15)	1.18 (0.16)		0.537
n (%)	34 (50)	41 (52)	58 (38)	133 (44)	
Glutathione (nM/ml), mean (SD)	1.65 (0.25)	1.65 (0.18)	1.71 (0.27)		0.371
n (%)	34 (50)	41 (52)	58 (38)	133 (44)	
Glutathione disulfide (nM/ml), mean (SD)	0.24 (0.03)	0.23 (0.04)	0.25 (0.04)		0.131
n (%)	34 (50)	41 (52)	58 (38)	133 (44)	
ratio (Glutathione/Glutathio ne disulfide), mean (SD)	6.97 (1.56)	7.37 (1.8)	7 (1.32)		0.435
n (%)	34 (50)	41 (52)	58 (38)	133 (44)	

849 *p*-values from one-way ANOVA.

850

851 **Figures**



852

853 **Figure 1. Identification and function of ASD associated and Non-TD associated**

854 **differentially expressed genes in maternal peripheral blood**

855 Differential expression analysis was performed in maternal peripheral blood

856 transcriptomes (n = 300) after adjustment for surrogate variables.


857 A) Identification of 1,912 differentially expressed genes (2,012 transcripts, p -value < 0.05)
858 compared between children diagnosed as ASD ($n = 67$) and TD ($n = 154$).

859 B) Identification of 1,919 differential expressed genes (1,987 transcripts, p -value < 0.05)
860 compared between children diagnosed as Non-TD ($n = 79$) and TD ($n = 154$). Two
861 transcripts located at *RFESD* and *TRG-AS1* were genome-wide significant in the Non-TD to
862 TD comparison and at an unadjusted p value in ASD to TD comparison (Supplementary
863 Table 2).

864 C) Venn diagram represents the overlap in differentially expressed transcripts (unadjusted
865 $p < 0.05$) identified in ASD to TD versus Non-TD to TD comparisons, which was greater than
866 expected by random using a Fisher's exact test (p -value < 0.001***).

867 D) Gene ontology (GO) and pathway analysis was performed on the 218 transcripts
868 differentially expressed in both ASD-TD and non-TD-TD comparisons, with significant
869 enrichments (Fisher's exact test, FDR p -value < 0.05). In contrast, the differentially
870 expressed transcripts uniquely associating with either ASD or non-TD were not
871 significantly enriched for any GO terms.

872



873

874 **Figure 2. Co-expression network modules with demographic factors and maternal**
 875 **peripheral blood one-carbon metabolites**

876 A) Heatmap of Z-scores of modules eigengenes with sample covariates with 27 co-

877 expression network modules on all 300 maternal blood samples. Each row represents a

878 different module eigengene and each column is the associated trait, which include child


879 clinical outcome, demographic factors, and maternal blood metabolite concentrations. The

880 matrix was calculated by Pearson correlation and *p*-values adjusted for the total number of

881 comparisons. Color represents the direction (red, positive correlation; blue, negative
882 correlation) and intensity reflects the significance. (^ unadjusted p -value < 0.05 and FDR
883 adjusted p -value > 0.05; * FDR adjusted p -value < 0.05)

884 B) Number of transcripts and hub genes from all 27 co-expressed modules are listed.

885



886

887 **Figure 3. “Greenyellow” module was positively associated with diagnosis and**

888 **negatively associated with folic acid and 5-MeTHF**


889 A) “Greenyellow” module eigengene was significantly associated with child diagnosis (one-
890 way ANOVA, unadjusted p -value < 0.05). Greenyellow eigengene values were higher in
891 maternal blood from ASD pregnancies than TD or non-TD pregnancies.

892 B) “Greenyellow” module eigengene level was significantly negatively associated with 5-
893 MeTHF concentrations in maternal blood (ANOVA, p -value < 0.05).

894 C) Bar graph shows gene ontology (GO) and pathway significant enrichments from the 224
895 transcripts in “greenyellow” module (Supplementary Table 8).

896 D) Transcripts (16857547, 16867905 and 16867910) from MBD3L3-5 genes encoding
897 proteins involved in methylation-CpG binding functions were significantly negatively
898 associated with “greenyellow” module eigengene.

899




900

901 **Figure 4. Eight weighted gene co-expression modules associated with maternal**
902 **betaine and DMG concentrations were strongly clustered**

903 A) Unsupervised hierarchical clustering dendrogram was performed with module
904 eigengenes, betaine and DMG. The height of each node represents the intergroup
905 dissimilarity. Similar nodes clustered together under one branch.

906 B) Unsupervised hierarchical clustering adjacency heatmap, with color and intensity
907 representing the degree of correlation (dark, high; light, low correlation).
908 Black box indicates the block of eight weighted gene co-expression modules associated
909 with betaine and DMG concentrations.
910



911

912 **Figure 5. Imputed cell type proportions in material peripheral blood associated with**
 913 **demographic factors and maternal nutrients**

914 A) Barplot of each cell type mean estimated proportion separated by children diagnosis
 915 outcomes using peripheral blood reference panel in CIBERSORT.

916 B) Heatmap of correlation between sample demographic factors and maternal nutrients

917 with cell type proportions. Each row represents a cell type proportion and columns

918 represent traits, including child diagnostic outcome, demographic factors, and maternal
919 blood nutrient concentrations. p -values adjusted for the total number of comparisons.
920 Color represents the direction (red, positive correlation; blue, negative correlation) and
921 intensity reflects the significance, * p -value < 0.05 after FDR correction.

922

923 **Additional Files**

924 **Supplementary Figures:**

925 **Supplementary Figure 1.** Surrogate variable analysis in MARBLES subjects.

926 **Supplementary Figure 2.** Three transcripts at *HLA-C* reached genome-wide significance
927 with diagnosis.

928 A, B and C show the expression level at each transcript. The y-axis shown the normalized
929 and adjusted expression level. The x-axis represented three diagnosis groups, ASD, Non-TD
930 and TD.

931 A) Transcript 17039281, F-test showed the significant association between expression and
932 diagnosis (unadjusted p -value = 3.16E-06, FDR adjusted p -value = 0.038). For ASD
933 compared with TD group, expression was significantly associated with ASD prior to
934 genome-wide correction (unadjusted p -value = 5.17E-04, FDR adjusted p -value = 0.57). In
935 Non-TD compared to TD, expression was also significant associated with Non-TD prior to
936 genome-wide correction (unadjusted p -value = 0.017, FDR adjusted p -value = 0.81).

937 B) Transcript 17041782, diagnosis (unadjusted p -value = 6.07E-06, FDR adjusted p -value =
938 0.046); ASD vs TD (unadjusted p -value = 5.83E-04, FDR adjusted p -value = 0.57); Non-TD
939 vs TD (unadjusted p -value = 0.025, FDR adjusted p -value = 0.84).

940 C) Transcript 17031781, diagnosis (unadjusted p -value = 7.96E-06, FDR adjusted p -value =
941 0.048); ASD vs TD (unadjusted p -value = 6.5E-04, FDR adjusted p -value = 0.57); Non-TD vs
942 TD (unadjusted p -value = 0.027, FDR adjusted p -value = 0.86).

943 **Supplementary Figure 3.** Gene ontology and pathway analysis using directed acyclic
944 graph (DAG) on the 218 transcripts common to ASD vs. TD and Non-TD vs. TD differentially
945 expressed gene lists.

946 **Supplementary Figure 4.** Co-expression network modules with diagnosis, demographic
947 factors, and maternal blood nutrient concentrations. The values in the cells represent
948 Pearson r (adjusted p -value). p -value were adjusted for all comparisons.

949 **Supplementary Figure 5.** Co-expression network modules with diagnosis, demographic
950 factors, and maternal blood nutrient concentrations. The values in the cells represent
951 Pearson r (p -value). p -value shown here were unadjusted p -value without adjustment.

952 **Supplementary Figure 6.** Unsupervised hierarchical clustering adjacency heatmap
953 correlation and p -value.

954 **Supplementary Figure 7:** Gene ontology and pathway analysis for the block of eight
955 weighted gene co-expression modules associated with betaine and DMG.

956 **Supplementary Figure 8:** Association network on hub genes from the block of eight
957 weighted gene co-expression modules associated with betaine and DMG.

958 **Supplementary Figure 9:** Heatmap of correlation between module eigengenes and cell
959 type proportions with FDR adjusted p -value.

960 **Supplementary Figure 10:** Heatmap of correlation between sample demographic factors
961 and nutrients and cell type proportions with FDR adjusted p -value.

962

963 **Supplementary Tables:**

964 **Supplementary Table 1:** Sample variables on RNA quality in MARBLES subjects.

965 **Supplementary Table 2:** Differential expression analysis on maternal gene expression and
966 diagnosis.

967 **Supplementary Table 3:** ASD related significant genes from differential expression
968 analysis.

969 **Supplementary Table 4:** Non-TD related significant genes from differential expression
970 analysis.

971 **Supplementary Table 5:** Weighted gene co-expression network module memberships.

972 **Supplementary Table 6:** Weighted gene co-expression network module features,
973 including number of transcripts and hub genes characters.

974 **Supplementary Table 7:** “Greenyellow” gene co-expression network module
975 memberships on 224 transcripts.

976 **Supplementary Table 8:** “Greenyellow” gene co-expression network module 224
977 transcripts gene ontology terms and gene lists.

978 **Supplementary Table 9:** Eight weighted gene co-expression modules block memberships
979 on 2,582 transcripts.

980 **Supplementary Table 10:** Cell type proportions in all 300 maternal peripheral blood
981 samples estimated with CIBERSORT.